Overview

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
Phase:
Phase 3
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd